先为达生物GLP-1新药申报上市，康方生物、正大天晴抗PD-1单抗新适应症申报上市，强生古塞奇尤单抗新给药方式获FDA批准

医药经济报11-25 20:59

先为达生物GLP-1新药申报上市近日，先为达生物开发的偏向型GLP-1受体激动剂新药——伊诺格鲁肽注射液的上市许可申请获中国国家药品监督管理局（NMPA）受理，用于成人2型糖尿病患者血糖控制适应症。根据先为达生物公开资料，伊诺格鲁肽是一种新型、脂肪酸修饰的长效GLP-1受体激动剂，只需每周皮下注射一次。该产品已完成糖尿病、减重的3期临床研究，部分结果在美国糖尿病大会、欧洲糖尿病大会先后发表，朱大龙...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2486708965?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-25 20:59","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2486708965","market":"us","top_or_hot":-1,"title":"先为达生物GLP-1新药申报上市，康方生物、正大天晴抗PD-1单抗新适应症申报上市，强生古塞奇尤单抗新给药方式获FDA批准","media":"医药经济报","content":"<div>\n<p>先为达生物GLP-1新药申报上市近日，先为达生物开发的偏向型GLP-1受体激动剂新药——伊诺格鲁肽注射液的上市许可申请获中国国家药品监督管理局（NMPA）受理，用于成人2型糖尿病患者血糖控制适应症。根据先为达生物公开资料，伊诺格鲁肽是一种新型、脂肪酸修饰的长效GLP-1受体激动剂，只需每周皮下注射一次。该产品已完成糖尿病、减重的3期临床研究，部分结果在美国糖尿病大会、欧洲糖尿病大会先后发表，朱大龙...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241125210622a254650e&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>先为达生物GLP-1新药申报上市，康方生物、正大天晴抗PD-1单抗新适应症申报上市，强生古塞奇尤单抗新给药方式获FDA批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n先为达生物GLP-1新药申报上市，康方生物、正大天晴抗PD-1单抗新适应症申报上市，强生古塞奇尤单抗新给药方式获FDA批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-25 20:59 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241125210622a254650e&s=b><strong>医药经济报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>先为达生物GLP-1新药申报上市近日，先为达生物开发的偏向型GLP-1受体激动剂新药——伊诺格鲁肽注射液的上市许可申请获中国国家药品监督管理局（NMPA）受理，用于成人2型糖尿病患者血糖控制适应症。根据先为达生物公开资料，伊诺格鲁肽是一种新型、脂肪酸修饰的长效GLP-1受体激动剂，只需每周皮下注射一次。该产品已完成糖尿病、减重的3期临床研究，部分结果在美国糖尿病大会、欧洲糖尿病大会先后发表，朱大龙...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241125210622a254650e&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4023","symbol_name":"应用软件","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241125210622a254650e&s=b","article_id":"2486708965","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241125210622a254650e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2486708965","pubTimestamp":1732539575,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"先为达生物GLP-1新药申报上市近日，先为达生物开发的偏向型GLP-1受体激动剂新药——伊诺格鲁肽注射液的上市许可申请获中国国家药品监督管理局受理，用于成人2型糖尿病患者血糖控制适应症。正大天晴彼时新闻稿表示，将就该联合疗法的新适应症向CDE递交上市申请。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4023":"应用软件","IE00BVYPNW00.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) ACC","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","BK4144":"石油与天然气的储存和运输","LU1732800096.USD":"摩根大通环球收益基金A (irc)","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BK4585":"ETF&股票定投概念","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1221951046.USD":"NORDEA 1 STABLE RETURN \"HM\" (USDHDG) INC","PD":"PagerDuty, Inc.","LU0234572021.USD":"高盛美国核心股票组合Acc","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","GLP":"全球合伙","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0122379950.USD":"贝莱德世界健康科学A2","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","IE00BVYPNV92.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) ACC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","IE00B3PB1722.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) INC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4581":"高盛持仓","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","BK4590":"PTP","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","JNJ":"强生","LU1032955483.USD":"NORDEA 1 STABLE RETURN \"HB\" (USDHDG) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0234570918.USD":"高盛全球核心股票组合Acc Close"},"translate_title":"Xianweida Bio's GLP-1 new drug was declared for marketing, Kangfang Bio and Chia Tai Tianqing anti-PD-1 monoclonal antibody new indications were declared for marketing, and Johnson & Johnson's new administration method of gusecchiumab was approved by the FDA","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PD":1,"GLP":1,"JNJ":1},"content_text":"先为达生物GLP-1新药申报上市近日，先为达生物开发的偏向型GLP-1受体激动剂新药——伊诺格鲁肽注射液的上市许可申请获中国国家药品监督管理局（NMPA）受理，用于成人2型糖尿病患者血糖控制适应症。根据先为达生物公开资料，伊诺格鲁肽是一种新型、脂肪酸修饰的长效GLP-1受体激动剂，只需每周皮下注射一次。该产品已完成糖尿病、减重的3期临床研究，部分结果在美国糖尿病大会、欧洲糖尿病大会先后发表，朱大龙教授牵头完成的2期临床研究结果也刊登在《自然》杂志子刊Nature Communication。根据先为达生物公开资料介绍，伊诺格鲁肽注射液（ecnoglutide injection，XW003）是一种新型、脂肪酸修饰的长效GLP-1受体激动剂，其分子全部由天然氨基酸组成，与其他GLP-1类似物相比，生产工艺更为简化，且可实现每周给药一次。作为偏向型的GLP-1受体激动剂，伊诺格鲁肽具有优异的体外活性，偏向于cAMP通路的激活而非GLP-1受体的细胞内化。在啮齿类动物模型中，与非偏向型GLP-1受体激动剂相比，伊诺格鲁肽具有更显著的血糖控制和体重减轻效果。康方生物/正大天晴抗PD-1单抗新适应症申报上市11月21日，中国国家药监局药品审评中心（CDE）官网公示，康方生物和正大天晴在研的抗PD-1抗体派安普利单抗注射液，以及正大天晴在研的盐酸安罗替尼胶囊上市申请获得受理。今年9月，派安普利单抗联合安罗替尼一线治疗晚期肝细胞癌的3期研究结果在欧洲肿瘤内科学会（ESMO）年会公布。正大天晴彼时新闻稿表示，将就该联合疗法的新适应症向CDE递交上市申请。由此推测，本次获受理的可能是一项联合疗法上市申请，用于一线治疗晚期肝细胞癌。截图来源：CDE官网派安普利单抗（penpulimab）是一款新型差异化抗PD-1单抗，该产品由康方生物研发，并由康方生物与正大天晴合资的正大天晴康方负责后续开发和商业化。目前，派安普利单抗已经在中国获批3项适应症，涵盖非小细胞肺癌、霍奇金淋巴瘤、鼻咽癌。此外，该产品一线治疗转移性鼻咽癌的上市申请已提交，治疗肝癌、胃癌等适应症的后期阶段临床研究也正在推进。安罗替尼（anlotinib）是正大天晴开发的新型小分子多靶点（VEGFR/PDGFR/FGFR/c-kit）酪氨酸激酶抑制剂（TKI），于2018年在中国首次获批上市，目前已经在中国获批多个肿瘤适应症。强生古塞奇尤单抗新给药方式获FDA批准11月22日，在刚刚获得 FDA 批准使用静脉注射（IV）诱导方案治疗溃疡性结肠炎的 Tremfya（古塞奇尤单抗，guselkumab）后，强生（Johnson & Johnson）现已提交申请，寻求批准该皮下（SC）注射剂用于诱导治疗，这将使 Tremfya 成为首个提供两种给药方式的 IL-23 抑制剂。此次提交基于 III 期 ASTRO 研究的支持。研究显示，在第 0、4 和 8 周给予 400 毫克皮下注射诱导剂量后，第 12 周达到了具有统计学意义的临床缓解。此外，研究还完成了所有次要终点，包括内镜改善和组织学-内镜黏膜改善，其安全性数据与以往研究结果一致。ASTRO 研究的详细结果计划在即将举行的医学会议上公布。目前，Tremfya 已获批用于治疗斑块型银屑病和银屑病关节炎。强生希望通过扩大适应症标签，将克罗恩病纳入其中，并已向 FDA 提交相关市场申请。同时，针对克罗恩病和溃疡性结肠炎的申请也已提交至欧洲监管机构。编辑：香草Biotech整合大提速！睿跃生物借壳，葆元医药、依生生物之后纳斯达克再迎中国浪潮？吉利德肿瘤药卖不动了？新药失利、裁员调整，并购豪赌如何翻盘？并购潮涌！中生、康缘、东北等连续出手，行业整合加速？医保创新结算方式、建立预付金制度，医院回款难破冰www.yyjjb.com.cn洞悉行业趋势长按关注医药经济报《医药经济报》学术公众号聚焦肿瘤学术前沿长按关注免疫时间《医药经济报》终端公众号记录药品终端产经大事件长按关注21世纪药店","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2486708965"}